“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...